000304475 001__ 304475
000304475 005__ 20250911114926.0
000304475 0247_ $$2doi$$a10.1097/WCO.0000000000001426
000304475 0247_ $$2pmid$$apmid:40916936
000304475 0247_ $$2ISSN$$a1350-7540
000304475 0247_ $$2ISSN$$a1473-6551
000304475 037__ $$aDKFZ-2025-01867
000304475 041__ $$aEnglish
000304475 082__ $$a610
000304475 1001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b0$$eLast author$$udkfz
000304475 245__ $$aIsocitrate dehydrogenase mutation and microenvironment in gliomas: do immunotherapy approaches matter?
000304475 260__ $$aLondon$$bLippincott Williams & Wilkins$$c2025
000304475 3367_ $$2DRIVER$$aarticle
000304475 3367_ $$2DataCite$$aOutput Types/Journal article
000304475 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757502246_23584$$xReview Article
000304475 3367_ $$2BibTeX$$aARTICLE
000304475 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304475 3367_ $$00$$2EndNote$$aJournal Article
000304475 500__ $$a#LA:D170# / epub
000304475 520__ $$aGliomas with mutations in the gene for isocitrate dehydrogenase (IDH) display a unique immune microenvironment that is distinct from IDH-wildtype gliomas. This unique immune microenvironment is shaped by 2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH. These features provide an opportunity to develop and test targeted immunotherapies for IDH-mutant gliomas.IDH-mutant gliomas are characterized by an immunosuppressive tumor immune microenvironment (TIME) that suppresses the infiltration and activation of tumor-specific T cells. This is owed both to direct effects of the oncometabolite 2-hydroxyglutarate on glioma-infiltrating T cells and myeloid cells and indirect effects on the chemotactic profile of tumor cells. These immunosuppressive effects are reversed by IDH inhibitors recently approved for the treatments of IDH-mutant gliomas. At the same time, clinical trials have demonstrated encouraging results for targeted immunotherapies using vaccines targeting the most frequent mutation IDH1R132H.The reversal of the immunosuppressive effects by IDH inhibitors has opened exciting avenues for combinatorial immunotherapies such as vaccines and immune checkpoint inhibitors.
000304475 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000304475 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304475 650_7 $$2Other$$aglioma
000304475 650_7 $$2Other$$aimmune checkpoint inhibitor
000304475 650_7 $$2Other$$aimmunotherapy
000304475 650_7 $$2Other$$aisocitrate dehydrogenase
000304475 650_7 $$2Other$$amicroenvironment
000304475 650_7 $$2Other$$avaccine
000304475 773__ $$0PERI:(DE-600)2026967-5$$a10.1097/WCO.0000000000001426$$pnn$$tCurrent opinion in neurology$$vnn$$x1350-7540$$y2025
000304475 909CO $$ooai:inrepo02.dkfz.de:304475$$pVDB
000304475 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304475 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000304475 9141_ $$y2025
000304475 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2024-12-13$$wger
000304475 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCURR OPIN NEUROL : 2022$$d2024-12-13
000304475 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000304475 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000304475 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000304475 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000304475 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000304475 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-13
000304475 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2024-12-13
000304475 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000304475 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000304475 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-13
000304475 9202_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000304475 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000304475 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000304475 980__ $$ajournal
000304475 980__ $$aVDB
000304475 980__ $$aI:(DE-He78)D170-20160331
000304475 980__ $$aI:(DE-He78)HD01-20160331
000304475 980__ $$aUNRESTRICTED